Format

Send to

Choose Destination
Z Rheumatol. 2019 Aug;78(6):500-510. doi: 10.1007/s00393-019-0633-8.

[State of the art: systemic lupus erythematosus].

[Article in German]

Author information

1
Poliklinik und Funktionsbereich für Rheumatologie und Hiller Forschungszentrum, Universitätsklinikum Düsseldorf, HHUD, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
2
Poliklinik und Funktionsbereich für Rheumatologie und Hiller Forschungszentrum, Universitätsklinikum Düsseldorf, HHUD, Moorenstr. 5, 40225, Düsseldorf, Deutschland. schneiderm@med.uni-duesseldorf.de.

Abstract

As long as we cannot cure diseases such as systemic lupus erythematosus (SLE), it must be our goal that people with SLE can live a largely normal life. It should not be dominated by the disease. The main goal is secondary prevention, i. e. the prevention of harm. In 2020 we want to make a better contribution to this aim. For this article on SLE, being fit for 2020 therefore means applying the basic concepts of care for patients with SLE on a regular basis. The focus is on the new concepts resulting from the new classification criteria, the optimized basic care (BASIC), the complex communication with those affected, the new EULAR recommendations for monitoring SLE, the integration of biologics into the treatment regimen, the targeted therapy (T-2-T) and thus the criteria low disease activity and remission, the question of new care structures for rare and complex systemic diseases and finally the outlook on future treatment concepts, the basis of which we will all create in the coming years. If we consistently apply the current options, we will be able to further improve the life situation and quality of life of those affected even without newly approved drugs.

KEYWORDS:

Biologics; Guidelines; Remission; Secondary prevention; Treat to target

PMID:
31028474
DOI:
10.1007/s00393-019-0633-8

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center